선택지 정리됨
Gestational trophoblastic disease / neoplasia: 국가별 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨희귀·유전 질환최종 확인 2026.06
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
임상시험 검색어
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
- Surgery, single-agent chemotherapy, combination chemotherapy including EMA/CO and other regimens, intrathecal chemotherapy and/or brain radiation in selected metastatic contexts, salvage surgery in selected chemoresistant contexts, clinical trials[1]Standard option (per NCI PDQ)Low-risk GTN; high-risk metastatic GTN; stage I-IV PSTT/ETT; recurrent or chemoresistant GTN. · NCI states there are no randomized trials establishing superiority among commonly used high-risk regimens; EMA/CO is presented because it is commonly used, not because NCI declares it universally superior. Do not infer individual eligibility, dosing, or insurance coverage from this summary. Confidence/conflicts: High for U.S. evidence-framework categories; regimen superiority and individual treatment selection remain uncertain as the source states.
United Kingdom
- Methotrexate with folinic acid rescue, actinomycin D, EMA-CO, EP-EMA, TP/TE, intrathecal methotrexate in selected brain/high-risk contexts, pembrolizumab for chemotherapy-resistant situations, specialist-center chemotherapy[2]Standard option (per Cancer Research UK)hCG monitoring and risk score are described; no molecular biomarker specified in the fetched source; Low-risk invasive mole/choriocarcinoma; high-risk disease; ultra-high-risk disease; chemotherapy resistance; brain-spread/high-risk intrathecal context. · This is UK cancer information, not a NICE appraisal or individual commissioning decision. Pembrolizumab is described for rare chemotherapy-resistant situations; do not generalize to all GTN or imply automatic access. Confidence/conflicts: High for UK chemotherapy and specialist-center framework; NICE/commissioning specifics were not independently fetched in this finding.
- Methotrexate with folinic acid rescue, actinomycin D, EMA-CO, EP-EMA, TP/TE, intrathecal methotrexate in selected brain/high-risk contexts, pembrolizumab for chemotherapy-resistant situations, specialist-center chemotherapy[2]Standard option (per Cancer Research UK)hCG monitoring and risk score are described; no molecular biomarker specified in the fetched source; Low-risk invasive mole/choriocarcinoma; high-risk disease; ultra-high-risk disease; chemotherapy resistance; brain-spread/high-risk intrathecal context. · This is UK cancer information, not a NICE appraisal or individual commissioning decision. Pembrolizumab is described for rare chemotherapy-resistant situations; do not generalize to all GTN or imply automatic access. Confidence/conflicts: High for UK chemotherapy and specialist-center framework; NICE/commissioning specifics were not independently fetched in this finding.
- Methotrexate with folinic acid rescue, actinomycin D, EMA-CO, EP-EMA, TP/TE, intrathecal methotrexate in selected brain/high-risk contexts, pembrolizumab for chemotherapy-resistant situations, specialist-center chemotherapy[2]Standard option (per Cancer Research UK)hCG monitoring and risk score are described; no molecular biomarker specified in the fetched source; Low-risk invasive mole/choriocarcinoma; high-risk disease; ultra-high-risk disease; chemotherapy resistance; brain-spread/high-risk intrathecal context. · This is UK cancer information, not a NICE appraisal or individual commissioning decision. Pembrolizumab is described for rare chemotherapy-resistant situations; do not generalize to all GTN or imply automatic access. Confidence/conflicts: High for UK chemotherapy and specialist-center framework; NICE/commissioning specifics were not independently fetched in this finding.
- Methotrexate with folinic acid rescue, actinomycin D, EMA-CO, EP-EMA, TP/TE, intrathecal methotrexate in selected brain/high-risk contexts, pembrolizumab for chemotherapy-resistant situations, specialist-center chemotherapy[2]Standard option (per Cancer Research UK)hCG monitoring and risk score are described; no molecular biomarker specified in the fetched source; Low-risk invasive mole/choriocarcinoma; high-risk disease; ultra-high-risk disease; chemotherapy resistance; brain-spread/high-risk intrathecal context. · This is UK cancer information, not a NICE appraisal or individual commissioning decision. Pembrolizumab is described for rare chemotherapy-resistant situations; do not generalize to all GTN or imply automatic access. Confidence/conflicts: High for UK chemotherapy and specialist-center framework; NICE/commissioning specifics were not independently fetched in this finding.
- Monitoring/advisory follow-up, chemotherapy, surgery in selected cases, specialist GTD clinic assessment[3]Standard option (per Imperial College Healthcare NHS Trust)hCG monitoring implied by GTD service follow-up; no molecular biomarker specified in the fetched Imperial page; GTD follow-up/monitoring; cases needing additional treatment; specialist clinic assessment. · This source documents a specialist-service pathway and broad treatment categories, not specific chemotherapy regimens, eligibility, or national commissioning rules. Confidence/conflicts: High for the Charing Cross specialist-service and broad treatment pathway; regimen-level detail should use dedicated treatment sources.
- Monitoring/advisory follow-up, chemotherapy, surgery in selected cases, specialist GTD clinic assessment[3]Standard option (per Imperial College Healthcare NHS Trust)hCG monitoring implied by GTD service follow-up; no molecular biomarker specified in the fetched Imperial page; GTD follow-up/monitoring; cases needing additional treatment; specialist clinic assessment. · This source documents a specialist-service pathway and broad treatment categories, not specific chemotherapy regimens, eligibility, or national commissioning rules. Confidence/conflicts: High for the Charing Cross specialist-service and broad treatment pathway; regimen-level detail should use dedicated treatment sources.
- Monitoring/advisory follow-up, chemotherapy, surgery in selected cases, specialist GTD clinic assessment[3]Standard option (per Imperial College Healthcare NHS Trust)hCG monitoring implied by GTD service follow-up; no molecular biomarker specified in the fetched Imperial page; GTD follow-up/monitoring; cases needing additional treatment; specialist clinic assessment. · This source documents a specialist-service pathway and broad treatment categories, not specific chemotherapy regimens, eligibility, or national commissioning rules. Confidence/conflicts: High for the Charing Cross specialist-service and broad treatment pathway; regimen-level detail should use dedicated treatment sources.
출처
- National Cancer Institute — national cancer agency evidence summary · national cancer agency evidence summary
- Cancer Research UK — UK cancer information / specialist-center treatment information · UK cancer information / specialist-center treatment information
- Imperial College Healthcare NHS Trust — NHS specialist-service information · NHS specialist-service information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.